Association of biomarkers of endothelial function, coagulation activation and kidney injury with persistent albuminuria in sickle cell anaemia.

Autor: Elsherif L; Center for Sickle Cell Disease, University of Tennessee Health Science Center, Memphis, Tennessee, USA., Tang Y; Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina, USA., Patillo KL; Office of Clinical Trials, University of Tennessee Health Science Center, Memphis, Tennessee, USA., Wichlan D; Division of Hematology, University of North Carolina, Chapel Hill, North Carolina, USA., Ogu UO; Center for Sickle Cell Disease, University of Tennessee Health Science Center, Memphis, Tennessee, USA., Landes K; Division of Hematology, The Ohio State University, Columbus, Ohio, USA., McCune P; Office of Clinical Trials, University of Tennessee Health Science Center, Memphis, Tennessee, USA., Scott LC; College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA., Gulledge W; College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA., Woodland WH; College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA., Nelson M; Center for Sickle Cell Disease, University of Tennessee Health Science Center, Memphis, Tennessee, USA., Loehr LR; Division of General Medicine and Epidemiology, University of North Carolina, Chapel Hill, North Carolina, USA., Cronin RM; Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA., Desai PC; Levine Cancer Institute - Atrium Health, Wake Forest School of Medicine, Charlotte, North Carolina, USA., Zhou LY; Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, Indiana, USA., Pollock DM; Division of Nephrology, University of Alabama at Birmingham, Birmingham, Alabama, USA., Zou F; Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina, USA., Cai J; Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina, USA., Derebail VK; Division of Nephrology and Hypertension, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Ataga KI; Center for Sickle Cell Disease, University of Tennessee Health Science Center, Memphis, Tennessee, USA.

Publikováno v: British journal of haematology [Br J Haematol] 2024 Nov; Vol. 205 (5), pp. 1963-1973. Date of Electronic Publication: 2024 Sep 03.

Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1-2 trial.

Autor: Gladwin MT; University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: mgladwin@som.umaryland.edu., Gordeuk VR; Division of Hematology and Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA., Desai PC; Levine Cancer Institute, Atrium Health, Wake Forest School of Medicine, Charlotte, NC, USA., Minniti C; Albert Einstein College of Medicine, New York, NY, USA., Novelli EM; Department of Medicine, Division of Hematology and Oncology, and Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA, USA., Morris CR; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA; Department of Pediatric Emergency Medicine, Children's Healthcare of Atlanta, Atlanta, GA, USA., Ataga KI; Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA., De Castro L; Department of Medicine, Division of Hematology and Oncology, and Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA, USA., Curtis SA; Icahn School of Medicine at Mount Sinai, New York, NY, USA., El Rassi F; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA; Georgia Comprehensive Sickle Cell Clinic at Grady Health System, Atlanta, GA, USA., Ford HJ; Pulmonary Hypertension Program, Division of Pulmonary and Critical Care Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Harrington T; Division of Hematology, Department of Medicine, University of Miami, Miami, FL, USA., Klings ES; The Pulmonary Center, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA., Lanzkron S; Sickle Cell Center for Adults, Johns Hopkins School of Medicine, Baltimore, MD, USA., Liles D; Brody School of Medicine East Carolina University, Greenville, NC, USA., Little J; University of North Carolina Comprehensive Sickle Cell Disease Program and Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Nero A; University of Texas Southwestern Medical Center, Dallas, TX, USA., Smith W; Division of General Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA., Taylor JG 6th; Center for Sickle Cell Disease, Departments of Medicine (Hematology and Oncology) and Microbiology and Immunology, Howard University College of Medicine, Washington, DC, USA; Department of Food and Human Nutrition Sciences, University of Manitoba, Winnipeg, MB, Canada., Baptiste A; Department of Medicine, New York-Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY, USA., Hagar W; Internal Medicine, Department of Pediatrics, University of California San Francisco, Benioff Children's Hospital Oakland, Oakland, CA, USA., Kanter J; Hematology Oncology, Department of Internal Medicine, University of Alabama Birmingham, Birmingham, AL, USA., Kinzie A; Sickle Cell Center of Southern Louisiana, Tulane University School of Medicine, New Orleans, LA, USA., Martin T; Medical University of South Carolina, Charleston, SC, USA., Rafique A; Sickle Cell Center of Southern Louisiana, Tulane University School of Medicine, New Orleans, LA, USA., Telen MJ; Division of Hematology, Department of Medicine, Duke University School of Medicine, and Duke Comprehensive Sickle Cell Center, Durham, NC, USA., Lalama CM; Division of General Internal Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; Center for Clinical Trials & Data Coordination, Division of General Internal Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Kato GJ; Department of Medicine, Division of Hematology and Oncology, and Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA, USA., Abebe KZ; Division of General Internal Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; Center for Clinical Trials & Data Coordination, Division of General Internal Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

Publikováno v: The Lancet. Haematology [Lancet Haematol] 2024 May; Vol. 11 (5), pp. e345-e357. Date of Electronic Publication: 2024 Mar 27.

Current Evidence and Rationale to Guide Perioperative Management, Including Transfusion Decisions, in Patients With Sickle Cell Disease.

Autor: Azbell RCG; From the Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio., Lanzkron SM; Department of Internal Medicine, Division of Hematology, Johns Hopkins School of Medicine., Desai PC; Department of Internal Medicine, Division of Hematology, The Ohio State Wexner Medical Center, Columbus, Ohio.

Publikováno v: Anesthesia and analgesia [Anesth Analg] 2023 Jun 01; Vol. 136 (6), pp. 1107-1114. Date of Electronic Publication: 2023 May 19.

The Evolving Landscape of Drug Therapies for Sickle Cell Disease.

Autor: Rai P; Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA., Desai PC; Department of Hematology, Levine Cancer Institute - Atrium Health, Charlotte, NC, USA., Ataga KI; Center for Sickle Cell Disease, University of Tennessee Health Scienter Center, 956 Court Avenue, Suite D324, Memphis, TN 38163, USA. Electronic address: kataga@uthsc.edu.

Publikováno v: Hematology/oncology clinics of North America [Hematol Oncol Clin North Am] 2022 Dec; Vol. 36 (6), pp. 1285-1312.

Potential of cell tracking velocimetry as an economical and portable hematology analyzer.

Autor: Gómez-Pastora J; William G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, 151 West Woodruff Avenue, Columbus, OH, 43210, USA. jennifer.gomez611@gmail.com., Weigand M; William G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, 151 West Woodruff Avenue, Columbus, OH, 43210, USA., Kim J; William G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, 151 West Woodruff Avenue, Columbus, OH, 43210, USA., Palmer AF; William G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, 151 West Woodruff Avenue, Columbus, OH, 43210, USA., Yazer M; Department of Pathology, University of Pittsburgh, 3636 Blvd of the Allies, Pittsburgh, PA, 15213, USA., Desai PC; Division of Hematology, Department of Internal Medicine, The Ohio State University, Lincoln Tower - 1100-D, 1800 Cannon Drive, Columbus, OH, 43210, USA., Zborowski M; Department of Biomedical Engineering, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, 44195, USA., Chalmers JJ; William G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, 151 West Woodruff Avenue, Columbus, OH, 43210, USA.

Publikováno v: Scientific reports [Sci Rep] 2022 Feb 01; Vol. 12 (1), pp. 1692. Date of Electronic Publication: 2022 Feb 01.